sn 23862 has been researched along with vadimezan in 2 studies
| Studies (sn 23862) | Trials (sn 23862) | Recent Studies (post-2010) (sn 23862) | Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) |
|---|---|---|---|---|---|
| 20 | 0 | 4 | 272 | 16 | 101 |
| Protein | Taxonomy | sn 23862 (IC50) | vadimezan (IC50) |
|---|---|---|---|
| Stimulator of interferon genes protein | Mus musculus (house mouse) | 1.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baguley, BC; Cliffe, S; Hill, RP; Rutland, M; Taylor, ML; Wilson, WR | 1 |
| Pruijn, FB; Wilson, WR | 1 |
2 other study(ies) available for sn 23862 and vadimezan
| Article | Year |
|---|---|
Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
Topics: Aniline Mustard; Animals; Antineoplastic Agents; Drug Synergism; Female; Flavonoids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Regional Blood Flow; Tirapazamine; Triazines; Xanthenes; Xanthones | 1994 |
Hypoxia-activated prodrugs as antitumour agents: strategies for maximizing tumour cell killing.
Topics: Aniline Mustard; Animals; Antineoplastic Agents; Cell Hypoxia; Mice; Neoplasms; Nitrogen Mustard Compounds; Prodrugs; Xanthenes; Xanthones | 1995 |